TWI272635B - Method of improving skin condition - Google Patents
Method of improving skin condition Download PDFInfo
- Publication number
- TWI272635B TWI272635B TW090102193A TW90102193A TWI272635B TW I272635 B TWI272635 B TW I272635B TW 090102193 A TW090102193 A TW 090102193A TW 90102193 A TW90102193 A TW 90102193A TW I272635 B TWI272635 B TW I272635B
- Authority
- TW
- Taiwan
- Prior art keywords
- substrate
- skin
- patent application
- collagen
- phase
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 26
- 239000000758 substrate Substances 0.000 claims abstract description 25
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 229910001868 water Inorganic materials 0.000 claims description 23
- 239000007788 liquid Substances 0.000 claims description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 5
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 206010013786 Dry skin Diseases 0.000 claims description 3
- 230000037336 dry skin Effects 0.000 claims description 3
- 229910052742 iron Inorganic materials 0.000 claims description 3
- -1 iron ions Chemical class 0.000 claims description 3
- 239000004973 liquid crystal related substance Substances 0.000 claims description 3
- 150000002500 ions Chemical class 0.000 claims description 2
- 239000007791 liquid phase Substances 0.000 claims 5
- 239000012071 phase Substances 0.000 claims 4
- 239000013078 crystal Substances 0.000 claims 1
- 238000002309 gasification Methods 0.000 claims 1
- 239000007790 solid phase Substances 0.000 claims 1
- 102000008186 Collagen Human genes 0.000 description 38
- 108010035532 Collagen Proteins 0.000 description 38
- 229920001436 collagen Polymers 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 24
- 239000000243 solution Substances 0.000 description 24
- 229910052500 inorganic mineral Inorganic materials 0.000 description 20
- 239000011707 mineral Substances 0.000 description 20
- 239000012266 salt solution Substances 0.000 description 16
- 238000010521 absorption reaction Methods 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 238000011282 treatment Methods 0.000 description 13
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 11
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 11
- 238000009472 formulation Methods 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000013589 supplement Substances 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 7
- 230000002079 cooperative effect Effects 0.000 description 7
- 239000002537 cosmetic Substances 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 238000001514 detection method Methods 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000008859 change Effects 0.000 description 4
- 230000001632 homeopathic effect Effects 0.000 description 4
- 238000012423 maintenance Methods 0.000 description 4
- 239000012488 sample solution Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 230000037319 collagen production Effects 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000011651 chromium Substances 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000001815 facial effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 230000003020 moisturizing effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 208000024794 sputum Diseases 0.000 description 2
- 210000003802 sputum Anatomy 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- VZXTWGWHSMCWGA-UHFFFAOYSA-N 1,3,5-triazine-2,4-diamine Chemical compound NC1=NC=NC(N)=N1 VZXTWGWHSMCWGA-UHFFFAOYSA-N 0.000 description 1
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- CKNYEUXAXWTAPK-UHFFFAOYSA-N 4-octoxy-4-oxobutanoic acid Chemical compound CCCCCCCCOC(=O)CCC(O)=O CKNYEUXAXWTAPK-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Natural products CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 241000251730 Chondrichthyes Species 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- 206010020649 Hyperkeratosis Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010039792 Seborrhoea Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010064127 Solar lentigo Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 241001135917 Vitellaria paradoxa Species 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- QCWXUUIWCKQGHC-UHFFFAOYSA-N Zirconium Chemical compound [Zr] QCWXUUIWCKQGHC-UHFFFAOYSA-N 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 229910052796 boron Inorganic materials 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- UQLDLKMNUJERMK-UHFFFAOYSA-L di(octadecanoyloxy)lead Chemical compound [Pb+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O UQLDLKMNUJERMK-UHFFFAOYSA-L 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 239000001307 helium Substances 0.000 description 1
- 229910052734 helium Inorganic materials 0.000 description 1
- SWQJXJOGLNCZEY-UHFFFAOYSA-N helium atom Chemical compound [He] SWQJXJOGLNCZEY-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000009434 installation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000171 lavandula angustifolia l. flower oil Substances 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- HZZOEADXZLYIHG-UHFFFAOYSA-N magnesiomagnesium Chemical compound [Mg][Mg] HZZOEADXZLYIHG-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000037312 oily skin Effects 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003761 preservation solution Substances 0.000 description 1
- 238000005086 pumping Methods 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 229940057910 shea butter Drugs 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- WFKWXMTUELFFGS-UHFFFAOYSA-N tungsten Chemical compound [W] WFKWXMTUELFFGS-UHFFFAOYSA-N 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000010937 tungsten Substances 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052726 zirconium Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N2/00—Magnetotherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/83—Electrophoresis; Electrodes; Electrolytic phenomena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/87—Application Devices; Containers; Packaging
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Radiology & Medical Imaging (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Apparatuses For Bulk Treatment Of Fruits And Vegetables And Apparatuses For Preparing Feeds (AREA)
- Fats And Perfumes (AREA)
- Lasers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/646,798 US5905265A (en) | 1996-05-21 | 1996-05-21 | Method of improving skin condition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TWI272635B true TWI272635B (en) | 2007-02-01 |
Family
ID=24594498
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW090102193A TWI272635B (en) | 1996-05-21 | 1997-05-21 | Method of improving skin condition |
| TW086106812A TW483020B (en) | 1996-05-21 | 1997-05-21 | Method of improving skin condition. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW086106812A TW483020B (en) | 1996-05-21 | 1997-05-21 | Method of improving skin condition. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5905265A (cg-RX-API-DMAC10.html) |
| JP (1) | JP2001508761A (cg-RX-API-DMAC10.html) |
| KR (1) | KR100450713B1 (cg-RX-API-DMAC10.html) |
| CN (1) | CN1123050C (cg-RX-API-DMAC10.html) |
| AR (1) | AR048562A1 (cg-RX-API-DMAC10.html) |
| AU (1) | AU708049B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2256348C (cg-RX-API-DMAC10.html) |
| CO (1) | CO4850561A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL127182A0 (cg-RX-API-DMAC10.html) |
| IN (1) | IN183686B (cg-RX-API-DMAC10.html) |
| TW (2) | TWI272635B (cg-RX-API-DMAC10.html) |
| WO (1) | WO1997044810A1 (cg-RX-API-DMAC10.html) |
| ZA (1) | ZA974421B (cg-RX-API-DMAC10.html) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1109744B1 (en) | 1998-07-27 | 2002-05-08 | John Nikolaj Hvarre | Device and preparation for the treatment of tap water and drinking water |
| US6290993B1 (en) * | 1999-07-23 | 2001-09-18 | E-L Management Corp. | Compositions containing mimosa phenolic compounds |
| JP2003137807A (ja) * | 2001-11-01 | 2003-05-14 | Miyagi Kagaku Kogyo Kk | コラーゲン産生促進剤、それを含む化粧品、食品および医薬品ならびに皮膚疾患の予防または改善用外用剤 |
| DE10223221A1 (de) * | 2002-05-24 | 2003-12-11 | Sebapharma Gmbh & Co Kg | Kosmetische Zusammensetzung mit hautentquellender Wirkung |
| JP2004167467A (ja) * | 2002-11-15 | 2004-06-17 | Lidic Inc | 振動情報記録水 |
| GR1004816B (el) * | 2003-05-07 | 2005-02-18 | Evalion Ανωνυμη Εταιρεια Παροχης Υπηρεσιων-Συμβουλευτικη-Εμπορικη | Μεθοδος μεταφορας συχνοτητων σε ουσιες μεσω κρυσταλλων και παρασκευη σκευασματων τα οποια περιεχουν τις συχνοτητες αυτες |
| JP2004337831A (ja) * | 2003-05-16 | 2004-12-02 | Lidic Inc | 生体の生命力を支援する振動情報の生成方法 |
| JP4916143B2 (ja) * | 2005-08-04 | 2012-04-11 | サッポロビール株式会社 | ビール酵母で発酵させたアルコール飲料からコラーゲン産生促進作用を有する組成物を製造する方法及びその組成物 |
| US20100181261A1 (en) * | 2009-01-22 | 2010-07-22 | Eagle Research LLC | Aqueous environment treatment apparatus and method |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3612315A1 (de) * | 1986-04-11 | 1987-10-22 | Kropp Werner | Substrat und verfahren sowie vorrichtung zu seiner herstellung |
| EP0538361A4 (en) * | 1990-07-06 | 1993-05-19 | Iit Research Institute | Method and apparatus for rendering medical materials safe |
| US5247179A (en) * | 1990-10-18 | 1993-09-21 | Hiroshi Tachibana | Activation energy providing device |
-
1996
- 1996-05-21 US US08/646,798 patent/US5905265A/en not_active Expired - Fee Related
-
1997
- 1997-05-13 JP JP54246197A patent/JP2001508761A/ja active Pending
- 1997-05-13 AU AU30028/97A patent/AU708049B2/en not_active Ceased
- 1997-05-13 CN CN97196632A patent/CN1123050C/zh not_active Expired - Fee Related
- 1997-05-13 IL IL12718297A patent/IL127182A0/xx unknown
- 1997-05-13 WO PCT/US1997/007936 patent/WO1997044810A1/en not_active Ceased
- 1997-05-13 KR KR10-1998-0709302A patent/KR100450713B1/ko not_active Expired - Fee Related
- 1997-05-13 CA CA002256348A patent/CA2256348C/en not_active Expired - Fee Related
- 1997-05-20 AR ARP970102131A patent/AR048562A1/es unknown
- 1997-05-21 IN IN1083MA1997 patent/IN183686B/en unknown
- 1997-05-21 TW TW090102193A patent/TWI272635B/zh not_active IP Right Cessation
- 1997-05-21 ZA ZA9704421A patent/ZA974421B/xx unknown
- 1997-05-21 CO CO97027714A patent/CO4850561A1/es unknown
- 1997-05-21 TW TW086106812A patent/TW483020B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20000011142A (ko) | 2000-02-25 |
| CA2256348C (en) | 2002-07-23 |
| IN183686B (cg-RX-API-DMAC10.html) | 2000-03-18 |
| CN1226338A (zh) | 1999-08-18 |
| ZA974421B (en) | 1997-12-22 |
| WO1997044810A1 (en) | 1997-11-27 |
| IL127182A0 (en) | 1999-09-22 |
| AR048562A1 (es) | 2006-05-10 |
| JP2001508761A (ja) | 2001-07-03 |
| CN1123050C (zh) | 2003-10-01 |
| CO4850561A1 (es) | 1999-10-26 |
| TW483020B (en) | 2002-04-11 |
| AU708049B2 (en) | 1999-07-29 |
| AU3002897A (en) | 1997-12-09 |
| CA2256348A1 (en) | 1997-11-27 |
| KR100450713B1 (ko) | 2004-12-03 |
| US5905265A (en) | 1999-05-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahrari et al. | The antimicrobial sensitivity of Streptococcus mutans and Streptococcus sangius to colloidal solutions of different nanoparticles applied as mouthwashes | |
| TW299233B (cg-RX-API-DMAC10.html) | ||
| Li | The biochemistry and physiology of metallic fluoride: action, mechanism, and implications | |
| Shin et al. | Efficacy of 5% minoxidil versus combined 5% minoxidil and 0.01% tretinoin for male pattern hair loss: a randomized, double-blind, comparative clinical trial | |
| JP2021059601A (ja) | マイクロバイオーム適合化粧品 | |
| Zeldich et al. | Enamel matrix derivative stimulates human gingival fibroblast proliferation via ERK | |
| Almukainzi et al. | Quality and safety investigation of commonly used topical cosmetic preparations | |
| JP4252460B2 (ja) | 皮膚外用剤組成物 | |
| TWI272635B (en) | Method of improving skin condition | |
| CN117137817B (zh) | 一种去残留组合物、敏感肌氨基酸洗面奶及其制备方法 | |
| CN109260059B (zh) | 一种具有祛痘和皮肤修复功效的精油组合物及应用 | |
| CN117224419A (zh) | 番泻苷c在制备皮肤美白淡斑护肤品中的应用及相关产品 | |
| CN109316478A (zh) | 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品 | |
| JPH11333498A (ja) | 純水の製造方法 | |
| JPH11128951A (ja) | 油脂類の分散性に優れた水 | |
| TWI226244B (en) | Cosmetic skin care compositions containing cumic alcohol | |
| Morokuma et al. | Hair growth stimulatory effect by a combination of 5‐aminolevulinic acid and iron ion | |
| CN115212153B (zh) | 一种何首乌营养液及其制备方法 | |
| JP2011241166A5 (cg-RX-API-DMAC10.html) | ||
| CN109528532A (zh) | 一种含有胆碱香草酸盐的护肤品及其制备方法 | |
| US20030035846A1 (en) | Water having a superior ability to disperse oil and fats | |
| CN115531244A (zh) | 一种组合物及其制备方法和应用 | |
| Jones et al. | Safety, tolerability, and pharmacokinetics of APD371, a highly selective CB2 agonist, in healthy adults | |
| van Tuyll van Serooskerken et al. | The porphyrias: Clinic, diagnostics, novel investigative tools and evolving molecular therapeutic strategies | |
| US20050031710A1 (en) | Method of personal care and cosmetic product preparation and composition using human blood type |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Annulment or lapse of patent due to non-payment of fees |